Remove 2030 Remove Immunization Remove Packaging
article thumbnail

Morepen Laboratories expands its domestic portfolio

Express Pharma

The product is offered in a 4×14 patient-compliant pack with day/night markers and matte foil packaging. per cent dissolution rate, anti-counterfeit Holosec packaging, and competitive pricing at 39.9 per cent dissolution rate, anti-counterfeit Holosec packaging, and competitive pricing at 39.9 The company notes its 98.23

article thumbnail

Investing in biologics excellence

pharmaphorum

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Could virtual reality become an essential tool for healthcare education?

pharmaphorum

According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This equates to approximately doubling the current medical workforce. VR for real world education.

Vaccines 145
article thumbnail

Pharmacologic Management of Crotalid Envenomation

Pharmacy Friday Pearls

Crotalidae Polyvalent Immune FAB (Ovine). Crofab ® [package insert]. Crotalidae Immune F(ab’)2 (Equine). Anavip ® [package insert]. 2001;161(16):2030-6. Patients can develop delayed or recurrent hematologic symptoms up to a week after treatment cessation, especially following a severe envenomation.

article thumbnail

Advancements in Biopharma Spur Innovation

PharmaTech

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52